- Home
- MYGN vs ZGN Comparison
MYGN vs ZGN Comparison
Compare MYGN & ZGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYGN | ZGN |
|---|---|---|
| Founded | 1991 | 1910 |
| Country | United States | Italy |
| Employees | N/A | 7450 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.6M | 2.4B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYGN | ZGN |
|---|---|---|
| Price | $4.75 | $9.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $7.64 | ★ $11.28 |
| AVG Volume (30 Days) | ★ 1.6M | 668.0K |
| Earning Date | 05-05-2026 | 03-20-2026 |
| Dividend Yield | N/A | ★ 1.45% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $7.19 | N/A |
| Revenue Next Year | $5.64 | $4.50 |
| P/E Ratio | ★ N/A | $25.94 |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.76 | $6.13 |
| 52 Week High | $10.30 | $11.93 |
Technical Indicators
Market Signals| Indicator | MYGN | ZGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 31.40 |
| Support Level | $3.93 | $8.59 |
| Resistance Level | $5.63 | $9.21 |
| Average True Range (ATR) | 0.35 | 0.40 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 32.58 | 0.43 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.